Patent 7964561 was granted and assigned to Advanced Technologies and Regenerative Medicine, LLC on June, 2011 by the United States Patent and Trademark Office.
Liquid formulations of bone morphogenetic proteins are provided for prolonged use at elevated temperatures. More specifically, the invention relates to liquid formulations comprising rhGDF-5, trehalose, and one or more biocompatible excipients that provide stability to the protein for at least 30 days at temperatures up to body temperature.